Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Spriggs

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Cancer|April 1, 1994
Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humansR P Rago, J M Miles, R L Sufit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancerC Aghajanian, D S Dizon, P Sabbatini, et al.
Journal of Virology|July 1, 1986
Genetic basis for altered pathogenesis of an immune-selected antigenic variant of reovirus type 3 (Dearing)K M Kaye, D R Spriggs, R Bassel-Duby, et al.
The Journal of Clinical Investigation|June 1, 1987
Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytesS A Cannistra, A Rambaldi, D R Spriggs, et al.
Gynecologic Oncology|December 31, 1997
Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancerC Aghajanian, C Brown, C O'flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 statusA Husain, X J Yan, N Rosales, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1989
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiationD E Hallahan, D R Spriggs, M A Beckett, et al.
Annals of Surgery|January 1, 1989
Chronic TNF infusion causes anorexia but not accelerated nitrogen lossH R Michie, M L Sherman, D R Spriggs, et al.
Gynecologic Oncology|April 1, 1996
The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancerH Gogas, F Shapiro, C Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1988
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolismM L Sherman, D R Spriggs, K A Arthur, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Cancer|April 1, 1994
Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humansR P Rago, J M Miles, R L Sufit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancerC Aghajanian, D S Dizon, P Sabbatini, et al.
Journal of Virology|July 1, 1986
Genetic basis for altered pathogenesis of an immune-selected antigenic variant of reovirus type 3 (Dearing)K M Kaye, D R Spriggs, R Bassel-Duby, et al.
The Journal of Clinical Investigation|June 1, 1987
Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytesS A Cannistra, A Rambaldi, D R Spriggs, et al.
Gynecologic Oncology|December 31, 1997
Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancerC Aghajanian, C Brown, C O'flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 statusA Husain, X J Yan, N Rosales, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1989
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiationD E Hallahan, D R Spriggs, M A Beckett, et al.
Annals of Surgery|January 1, 1989
Chronic TNF infusion causes anorexia but not accelerated nitrogen lossH R Michie, M L Sherman, D R Spriggs, et al.
Gynecologic Oncology|April 1, 1996
The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancerH Gogas, F Shapiro, C Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1988
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolismM L Sherman, D R Spriggs, K A Arthur, et al.
Pageof 10